Melanotan 2: Tanning Peptide, Libido, and What You Need to Know

Melanotan 2 (MT-2) is a synthetic analog of alpha-MSH (alpha-melanocyte-stimulating hormone) — a naturally occurring peptide that activates melanocortin receptors throughout the body. Developed in the 1980s at the University of Arizona in the search for a safer alternative to UV tanning (the original hypothesis: if you could tan without sun, you might reduce skin cancer), MT-2 produces powerful UV-independent melanin production but also triggers significant effects on libido, appetite suppression, and other melanocortin-mediated functions.

How MT-2 Works: Melanocortin Receptors

Alpha-MSH signals through five melanocortin receptors (MC1R-MC5R), each with distinct tissue distribution and effects. MT-2 activates MC1R, MC3R, MC4R, and MC5R — it is a non-selective melanocortin agonist, which explains its diverse effects:

MC1R (melanocytes): Triggers melanin synthesis, causing skin darkening. MT-2 activates this receptor far more potently than endogenous alpha-MSH.

MC3R (hypothalamus, immune system): Involved in energy homeostasis. MC3R activation contributes to MT-2's appetite-suppressing effects.

MC4R (CNS, sexual arousal centers): Mediates the aphrodisiac and erection-promoting effects. This led to the development of bremelanotide (PT-141) as an FDA-approved treatment for hypoactive sexual desire disorder in women.

MC5R (exocrine glands): Effects on secretory function.

Tanning Effects

MT-2 produces melanogenesis — the synthesis and redistribution of melanin pigment — in a dose-dependent manner. Unlike UV tanning, which causes local melanin darkening in sun-exposed areas, MT-2 produces systemic tanning because melanocytes throughout the body are activated.

The tanning effect requires some UV exposure to fully develop — MT-2 loads melanocytes with melanin precursors, but light activation completes the process. Users typically reduce UV exposure time significantly compared to conventional tanning while achieving a deeper, more even tan.

Typical protocols involve loading doses of 0.5-1 mg subcutaneously daily for 1-2 weeks until desired pigmentation is achieved, then maintenance doses of 0.5-1 mg every 1-2 weeks.

Libido and Sexual Effects

MT-2's effect on sexual function is pronounced and was one of its early clinical observations. In healthy male volunteers in early Arizona trials, MT-2 produced spontaneous erections in a significant proportion of subjects — an unexpected finding that redirected the research program. Subsequent trials confirmed MT-2 increases sexual desire and arousal in both men and women.

This libido-enhancing effect is mediated through MC4R in the hypothalamus and limbic system. Bremelanotide (PT-141), a closely related peptide that specifically activates MC4R more selectively, was developed from these observations and approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women.

Side Effects and Risks

MT-2's non-selective receptor activity produces predictable side effects:

Nausea: Very common, particularly at higher doses or rapid dose increases. Taking MT-2 before sleep or using antiemetics mitigates this.

Flushing and yawning: Both are MC4R-mediated effects seen at standard doses.

Mole darkening: MT-2 darkens existing melanocytic lesions. This is cosmetically bothersome but also raises theoretical concern about activating potentially dysplastic nevi.

Melanoma risk: The most serious theoretical concern. While MT-2 does not cause moles or cancer, darkening existing atypical moles could theoretically promote dysplasia. This has not been demonstrated in controlled studies but warrants caution in individuals with atypical or numerous moles.

Priapism: Prolonged erections (more than 4 hours) have been reported, requiring medical attention.

Regulatory Status

MT-2 is not FDA-approved and is not legal to sell for human use in the US, UK, Australia, or most of Europe. It is widely available as a "research chemical" online. The quality, purity, and dosing accuracy of unregulated MT-2 products is highly variable and represents a significant safety concern.

FAQ

Is melanotan 2 the same as bremelanotide (PT-141)? Closely related but distinct. Bremelanotide lacks the C-terminus of MT-2, making it more selective for MC3R/MC4R and eliminating most of the tanning effect. PT-141 is FDA-approved for sexual dysfunction; MT-2 is not approved for any indication.

Does MT-2 cause skin cancer? No direct evidence of carcinogenesis. The concern is theoretical: darkening atypical moles could mask changes and theoretically promote dysplasia. Annual dermatologic examination is prudent for MT-2 users.

How long does the tan from MT-2 last? Melanin deposited through MT-2 activation fades at the same rate as UV tanning — typically 2-4 weeks after discontinuation. Maintenance doses extend the tan.

Related Articles

• Afamelanotide: FDA-Approved Melanocyte Peptide
• AOD-9604: HGH Fragment for Fat Loss
• Argireline: The Topical Peptide Alternative to Botox?
• Bacteriostatic Water for Peptides: Why It Matters and How to Use It
• Best Peptide Stacks for Recovery, Fat Loss, and Longevity

Track your supplements in Optimize.